Expression of Ezrin and Phosphorylated Ezrin (pEzrin) in Pancreatic Ductal Adenocarcinoma

REFERENCES

• Niggli, V.; Rossy, J. Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol 2008, 40, 344–349.
   PubMed Web of Science ®Google Scholar
• Weng, W.H.; Ahlén, J.; Aström, K.; Lui, W.O.; Larsson, C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005, 11, 6198–6204.
   PubMed Web of Science ®Google Scholar
• Zeng, H.; Xu, L.; Xiao, D.; Zhang, H.; Wu, X.; Zheng, R.; Li, Q.; Niu, Y.; Shen, Z.; Li, E. Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem 2006, 54, 889–896.
   PubMed Web of Science ®Google Scholar
• Torer, N.; Kayaselcuk, F.; Nursal, T.Z.; Yildirim, S.; Tarim, A.; Nòyan, T.; Karakayali, H. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol 2007, 96, 419–423.
   PubMed Web of Science ®Google Scholar
• Bal, N.; Yildirim, S.; Nursal, T.Z.; Bolat, F.; Kayaselcuk, F. Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol 2007, 13, 3726–3729.
   PubMed Web of Science ®Google Scholar
• Köbel, M.; Langhammer, T.; Hüttelmaier, S.; Schmitt, W.D.; Kriese, K.; Dittmer, J.; Strauss, H.G.; Thomssen, C.; Hauptmann, S. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 2006, 19, 581–587.
   PubMed Web of Science ®Google Scholar
• Köbel, M.; Gradhand, E.; Zeng K.; Schmitt, W.D.; Kriese, K.; Lantzsch, T.; Wolters, M.; Dittmer, J.; Strauss, H.G.; Thomssen, C.; Hauptmann, S. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 2006, 25, 121–130.
   PubMed Web of Science ®Google Scholar
• Bruce, B.; Khanna, G.; Ren, L.; Landberg, G.; Jirström, K.; Powell, C.; Borczuk, A.; Keller, E.T.; Wojno, K.J.; Meltzer, P.; Baird, K.; McClatchey, A.; Bretscher, A.; Hewitt, S.M.; Khanna, C. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007, 24, 69–78.
   PubMed Web of Science ®Google Scholar
• Bretscher, A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 1999, 11, 109–116.
   PubMed Web of Science ®Google Scholar
• Barret, C.; Roy, C.; Montcourrier, P.; Mangeat, P.; Niggli, V. Mutagenesis of the phosphatidylinositol 4,5-bisphosphate (PIP(2)) binding site in the NH(2)-terminal domain of ezrin correlates with its altered cellular distribution. J Cell Biol 2000, 151, 1067–1080.
   PubMed Web of Science ®Google Scholar
• Brown, K.L.; Birkenhead, D.; Lai, J.C.; Li, L.; Li, R.; Johnson, P. Regulation of hyaluronan binding by F-actin and colocalization of CD44 and phosphorylated ezrin/radixin/moesin (ERM) proteins in myeloid cells. Exp Cell Res 2005, 303, 400–414.
   PubMed Web of Science ®Google Scholar
• Tran, Quang C.; Gautreau, A.; Arpin, M.; Treisman, R. Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J 2000, 19, 4565–4576.
   PubMed Web of Science ®Google Scholar
• Gautreau, A.; Poullet, P.; Louvard, D.; Arpin, M. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999, 96, 7300–7305.
   PubMed Web of Science ®Google Scholar
• Maresso, A.W.; Deng, Q.; Pereckas, M.S.; Wakim, B.T.; Barbieri, J.T. Pseudomonas aeruginosa ExoS ADP-ribosyltransferase inhibits ERM phosphorylation. Cell Microbiol 2007, 9, 97–105.
   PubMed Web of Science ®Google Scholar
• Maresso, A.W.; Baldwin, M.R.; Barbieri, J.T. Ezrin/radixin/moesin proteins are high affinity targets for ADP-ribosylation by Pseudomonas aeruginosa ExoS. J Biol Chem 2004, 279, 38402–38408.
   PubMed Web of Science ®Google Scholar
• Jia, J.; Wang, Y.; Zhou, L.; Jin, S. Expression of Pseudomonas aeruginosa toxin ExoS effectively induces apoptosis in host cells. Infect Immun 2006, 74, 6557–6570.
   PubMed Web of Science ®Google Scholar
• Amara, N.; Palapattu, G.S.; Schrage, M.; Gu, Z.; Thomas, G.V.; Dorey, F.; Said, J.; Reiter, R.E. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001, 61, 4660–4665.
   PubMed Web of Science ®Google Scholar
• Yu, Y.; Khan, J.; Khanna, C.; Helman, L.; Meltzer, P.S.; Merlino, G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004, 10, 175–181.
   PubMed Web of Science ®Google Scholar
• Khanna, C.; Wan, X.; Bose, S.; Cassaday, R.; Olomu, O.; Mendoza, A.; Yeung, C.; Gorlick, R.; Hewitt, S.M.; Helman, L.J. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004, 10, 182–186.
   PubMed Web of Science ®Google Scholar
• LinksAkisawa, N.; Nishimori, I.; Iwamura, T.; Onishi, S.; Hollingsworth, M.A. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 1999, 258, 395–400.
   PubMed Web of Science ®Google Scholar
• Kocher, H.M.; Sandle, J.; Mirza, T.A.; Li, N.F.; Hart, I.R. Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut 2009, 58, 271–284.
   PubMed Web of Science ®Google Scholar
• Sarrió, D.; Rodríguez-Pinilla, S.M.; Dotor, A.; Calero, F.; Hardisson, D.; Palacios, J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 2006, 98, 71–79.
   PubMed Web of Science ®Google Scholar
• Yeh, T.S.; Tseng, J.H.; Liu, N.J.; Chen, T.C.; Jan, Y.Y.; Chen, M.F. Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg 2005, 140, 1184–1190.
   PubMed Web of Science ®Google Scholar
• Krishnan, K.; Bruce, B.; Hewitt, S.; Thomas, D.; Khanna, C.; Helman, L.J. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006, 23, 227–236.
   PubMed Web of Science ®Google Scholar
• Jiang, B.H.; Liu, L.Z. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008, 8, 19–26.
   PubMed Web of Science ®Google Scholar
• Jiang, B.H.; Liu, L.Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008, 1784, 150–158.
   PubMed Web of Science ®Google Scholar